BioCentury
ARTICLE | Company News

Almirall, Quintiles sales and marketing update

August 6, 2012 7:00 AM UTC

Almirall and Quintiles partnered to promote Almirall's respiratory products in the U.K. The deal includes aclidinium bromide, which was approved last month in the EU, Iceland and Norway as Bretaris/ Eklira Genuair as maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). The drug is also approved in the U.S. as Tudorza Pressair for the long-term maintenance treatment of bronchospasm associated with COPD. Details were not disclosed (see BioCentury, July 30).

Forest Laboratories Inc. (NYSE:FRX, New York, N.Y.), which has U.S. rights to the product from Almirall, plans to launch the product next quarter, while Almirall plans to launch it this year with co-commercialization partner Menarini Group (Florence, Italy). ...